{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:04:57Z","timestamp":1790229897014,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate real-world outcomes of faricimab in treating diabetic macular edema (DMO) in treatment-naive and treatment-switch patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective audit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All patients with DMO initiating 6 mg faricimab at a London hospital between 01\/01\/2022-02\/02\/2024 were included. The protocol comprised four four-weekly loading doses followed by a treat-and-extend regimen tailored to response. Data collected included demographics, best-corrected visual acuity (BCVA), and central macular thickness (CMT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, 65 patients (87 eyes) received faricimab; 34 eyes (39.1%) were treatment-naive, and 53 eyes (60.9%) had switched from other treatments. In the treatment-naive group (24 patients; mean follow-up 8 months, SD = 3.8; 3\u20138 injections), mean age was 66 years (SD = 10), baseline VA: 59.5 EDTRS (SD = 13), and CMT: 485.1 \u03bcm (SD = 80), reducing to 327.2 \u03bcm (SD = 70;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). Final VA was 62.7 EDTRS (SD = 14;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.259). The treatment-switched group (41 patients, 53 eyes) had a mean age of 65 (SD = 11) years. A total of 32 eyes (60.4%) had a single prior treatment; 25 had received aflibercept, four eyes had received ranibizumab, and three eyes had received dexamethasone implants. The other 21 (39.6%) eyes had combinations of these medications. Patients received 2\u201311 faricimab injections. Mean follow-up was 8.4 months (SD = 3.9), initial VA: 59.7 EDTRS (SD = 12.9), and CMT: 439.5 \u03bcm (SD = 102), decreasing to 366.9 \u03bcm (SD = 80.7) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001); final VA was 61.4 (SD = 15.4) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.55).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Faricimab significantly reduced CMT in both groups, with a greater reduction in treatment-naive eyes. VA improvement was, however, not statistically significant. Further studies are warranted to explore factors influencing visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_930_25","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:13:16Z","timestamp":1761667996000},"page":"1596-1601","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Real-world outcomes of faricimab in treating diabetic macular edema up to two years"],"prefix":"10.4103","volume":"73","author":[{"given":"Tanvi","family":"Khetan","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Shah","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyancaa","family":"Jeyabaladevan","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Vithlani","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"R1-20260419","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09286580701396720","article-title":"Overview of epidemiologic studies of diabetic retinopathy","volume":"14","author":"Klein","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"R2-20260419","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R3-20260419","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from two phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R4-20260419","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R5-20260419","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R6-20260419","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"R7-20260419","first-page":"274","article-title":"VEGF-A\/Ang-2 neutralization causes sustained prevention of subretinal macrophage infiltration in a mouse model of spontaneous choroidal neovascularization [abstract]","volume":"62","author":"Canonica","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20260419","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"R9-20260419","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"R12-20260419","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2024.2336087","article-title":"Global experience of faricimab in clinical settings\u2014a review","volume":"24","author":"Sharma","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"R13-20260419","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s41669-023-00465-4","article-title":"Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): A UK analysis","volume":"8","author":"B\u00fchrer","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"R14-20260419","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.3390\/jcm13154508","article-title":"Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to faricimab","volume":"13","author":"Wolfrum","year":"2024","journal-title":"J Clin Med"},{"key":"R15-20260419","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment-resistant diabetic macular edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R16-20260419","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME)","volume":"13","author":"Giancipoli","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R17-20260419","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R18-20260419","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/24741264221138722","article-title":"Relationship between macular thickness and visual acuity in the treatment of diabetic macular edema with anti-VEGF therapy: Systematic review","volume":"7","author":"Wang","year":"2022","journal-title":"J Vitreoretin Dis"},{"key":"R19-20260419","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/eye.2013.196","article-title":"United Kingdom National Ophthalmology Database Study: Diabetic retinopathy; report 1: Prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services","volume":"27","author":"Keenan","year":"2013","journal-title":"Eye (Lond)"},{"key":"R20-20260419","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/medicina59040665","article-title":"Short-term outcomes of intravitreal faricimab injection for diabetic macular edema","volume":"59","author":"Kusuhara","year":"2023","journal-title":"Medicina (Kaunas)"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_930_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:36Z","timestamp":1787837136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_930_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_930_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-04-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}